RVMD - Revolution Medicines Inc

-

$undefined

N/A

(N/A)

Revolution Medicines Inc NasdaqGS:RVMD Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Location: 700 Saginaw Drive, Redwood City, CA, 94063, United States | Website: https://www.revmed.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.312B

Cash

2.103B

Avg Qtr Burn

-147.8M

Short % of Float

11.22%

Insider Ownership

1.99%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RMC-6236 Details
RAS mutant Non-small cell lung carcinoma

Phase 3

Data readout

Daraxonrasib (RMC-6236) Details
Pancreatic ductal adenocarcinoma , Cancer

Phase 3

Data readout

Daraxonrasib (RMC-6236) Details
Pancreatic ductal adenocarcinoma , Cancer

Phase 3

Initiation

Daraxonrasib (RMC-6236) Details
Pancreatic ductal adenocarcinoma , Cancer

Phase 3

Initiation

RMC-5552 (mTORC1 inhibitor) Details
Breast cancer, Renal cell carcinoma, Glioblastoma, Solid tumor/s, Cancer

Phase 1b

Data readout

RMC-4630 + sotorasib Details
Non-small cell lung carcinoma, Cancer

Phase 1b

Data readout

RMC-6291 (KRASG12C) Details
Solid tumor/s, Cancer

Phase 1

Data readout

RMC-6291+ pembrolizumab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

RMC-6236+ pembrolizumab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Update

RMC-9805 (KRASG12D) Details
Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Cancer

Phase 1

Update

RMC-6236 + RMC-6291 Details
Solid tumor/s, Cancer

Phase 1

Update

RMC-6236 (RASMULTI) Details
Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Cancer

Phase 1

Update

RMC-5127 Details
no known indication

Phase 1

Initiation

RMC-4630 (SHP2 inhibitor) Details
Colorectal cancer , Solid tumor/s, Cancer

Failed

Discontinued